We have previously reported the isolation of a membrane-attack-complex-inhibiting protein (MIP) from human erythrocyte membranes [Watts, Patel & Morgan (1987) Complement 4, 236] and the production of polyclonal antibodies to this protein. Here we report the identification in plasma, urine, saliva and cerebrospinal fluid of a protein immunochemically identical with the membrane-derived MIP. The protein has been isolated from plasma by immunoaffinity chromatography on an anti-(erythrocyte MIP)-Sepharose column and shown by SDS/polyacrylamide-gel electrophoresis to be of similar molecular mass to the erythrocyte protein (55 kDa non-reduced and 65 kDa under reducing conditions). Monoclonal antibodies have been raised against plasma MIP and used to establish a two-site enzyme-linked immunoadsorbent assay, enabling quantification of MIP in plasma, urine and cerebrospinal fluid. Plasma MIP, though not able to incorporate spontaneously into membranes, was deposited on heterologous and homologous erythrocyte membranes during complement activation in a C8-dependent manner. Depletion of MIP from plasma resulted in enhancement of the lytic capacity of the plasma on heterologous erythrocytes.
INTRODUCTION
Activation of complement leads to the production of biologically active molecules, including anaphylactic and chemotactic factors and the cytolytic membraneattack complex (MAC). In order to limit damage to host tissues it is therefore essential that activation is strictly controlled. Numerous fluid-phase and membrane-associated proteins have been demonstrated to inhibit autologous complement at the level of the C3/C5 convertases, thereby preventing completion of the cascade and restricting lysis of homologous cells (Mollnes & Lachmann, 1988) . The demonstration that reactive lysis, employing purified terminal components, is species-restricted provides evidence that assembly of the MAC is also under specific control (Yamamato, 1977; Hansch et al., 1981; Hu & Shin, 1984) . Plasma S-protein and C8 both exert control at this stage by binding to the fluid-phase C5b-7 complex, hence preventing its insertion into membranes (Podack et al., 1984; Nemerov et al., 1979; Zeitz et al., 1983) . Recently, two groups have described membraneassociated proteins which also have MAC-inhibitory properties, C8 binding protein (C8bp), so-called because of its affinity for C8 , and homologous restriction factor (HRF) (Zalman et al., 1986) . These proteins have been isolated from human erythrocyte membranes and identified on human peripheral blood cells. They exert their inhibitory effects at the stage of C8 and/or C9 binding and insertion into the MAC, although the exact mechanisms of action have yet to be elucidated.
We have also isolated a MAC-inhibiting protein (MIP) from human erythrocyte membranes (Watts et al., 1987) . Functional and molecular characterization of this protein demonstrates close similarities with C8bp and HRF, suggesting that all these proteins are identical.
In the present study we have employed antibodies produced to our cell-membrane-derived MIP to demonstrate the presence of fluid-phase MIP in normal plasma and other biological fluids. The protein has been isolated from plasma and demonstrated to be functionally active. Monoclonal antibodies raised against plasmaderived MIP detect molecules of identical size in membranes and in plasma, providing evidence for the identity of MIP Normal human serum (NHS) was obtained from adult volunteers and stored in portions at -70 'C. Sera specifically depleted of C8 (NHS -C8) or C9 (NHS -C9) were produced by passage of NHS over monoclonal anti-C8-or anti-C9-Sepharose columns respectively (Abraha et al., 1988; Morgan et al., 1983) . Proteins Human C9 and C8 were purified by immunoaffinity chromatography on immobilized monoclonal antibodies, as detailed previously (Morgan et al., 1983; Abraha et al., 1988) .
MAC-inhibiting protein (MIP) was initially purified from human erythrocyte membranes utilizing methods essentially similar to those used by Zalman et al. (1986) for the isolation of HRF. Briefly, deoxycholate-solubilized, haemoglobin-free human erythrocyte membranes were subjected to affinity chromatography on a human C9-Sepharose column equilibrated in column buffer (20 mM-Tris/HCl, 50 mM-NaCl, 0.02 % deoxycholate, pH 8.4). After extensive washing with the same buffer the bound protein was eluted with the above buffer containing 2 M-NaCl. Later preparations utilized a solidphase anti-MIP column, produced as described below, in place of the C9-Sepharose column, bound protein being eluted with 2 M-KBr in column buffer as described below for MIP purification from plasma. Antibodies Monoclonal anti-C9 and anti-C8 were produced as previously detailed (Morgan et al., 1983; Abraha et al., 1988 (Galfre & Milstein, 1981) as described previously (Morgan et al., 1983 Membrane-attack-complex-inhibiting protein removed by gel filtration on an Ultrogel AcA44 column which had previously been equilibrated in TBS/0.02 %0 sodium deoxycholate and the protein was eluted in the same buffer. Depletion of MIP from plasma Plasma depleted of C8 and C9, as described above, was passed over the anti-MIP column. This resulted in the removal of about 80 % of the plasma MIP. Physiological amounts of C8 and C9 were added back to the MIP-depleted plasma and to control plasma which had been depleted of C8 and C9 but not of MIP. The haemolytic activity of control and MIP-depleted plasma was then assessed by measurement of haemolysis of antibody-sensitized sheep erythrocytes using standard methods (Whaley, 1985) . Purified MIP was also added back to portions of the MIP-depleted plasma to assess the effects of repletion on haemolytic activity. E.l.i.s.a. assay for MIP in biological fluids
In order to quantify the amount of MIP present in biological fluids a two-site e.l.i.s.a. assay was established utilizing polyclonal anti-MIP as first antibody and monoclonal anti-MIP as second antibody. Polyclonal anti-MIP IgG at a final concentration of 5 ,g/ml in phosphate-buffered saline was incubated in the wells of microtitre plates (Flow Laboratories) overnight at 4 'C. The plates were then washed twice in PBS containing 0.1 % Tween 20 and various dilutions of plasma, cerebrospinal fluid, urine or purified MIP in PBS added. After incubation at 37 'C for 1 h the wells were again washed and monoclonal anti-MIP antibody MIP-G3 was added at a final concentration of 2 #tg/ml in PBS.
The plates were again incubated at 37 'C for 1 h, washed and peroxidase-labelled goat anti-(mouse IgG) antibody at a final dilution of 1:1000 in PBS was added. After a further 1 h at 37 'C the plate was washed, peroxidase substrate (1,2-diphenylenediamine dihydrochloride; Pierce) was added and colour allowed to develop for 2 min. The reaction was then stopped with 10 % H2SO4 and the A492 in the wells read using a Titertek Multiscan microplate reader. Quantification of MIP in samples was achieved by comparison of results with standard curves produced using purified MIP. Sample collection Plasma samples for assay were collected from ten normal laboratory personnel into EDTA and were stored at -20 'C prior to assay. 
RESULTS

Deposition of MIP-reactive material on heterologous and homologous erythrocytes
Immunoblotting of sheep erythrocyte membranes with polyclonal anti-MIP antibody showed that no anti-MIPreactive material was present on these cells. However, after these erythrocytes had been antibody-sensitized and incubated with NHS, immunoblotting revealed a sharp MIP-reactive band of 65 kDa and a faint band at 85 kDa, identical with MIP detected on immunoblots of human erythrocyte membranes (Fig. 1, lane 4) . Controls, including unsensitized or antibody-sensitized sheep erythrocytes incubated with buffer alone did not reveal any MIP-reactive material but unsensitized erythrocytes incubated with NHS showed faint bands on immunoblotting, perhaps reflecting the low level of complement activation occurring even without sensitization (Fig. 1 (Fig. 2) . MIP in serum and other biological fluids The experiments described above suggested that MIP was present in NHS and was deposited on heterologous and homologous erythrocytes during complement activation. In order to investigate this possibility further serum was subjected to SDS/PAGE and after electroblotting onto nitrocellulose was probed with polyclonal anti-MIP antibody. The polyclonal anti-MIP antibody used in these studies showed weak cross-reaction with both C8 and C9 in e.l.i.s.a. assays (results not shown). Therefore sera specifically depleted either of C9 alone or of C8 and C9 were also examined. As shown in Fig. 3 , lane 1, a single band of 65 kDa was detected by the polyclonal anti-MIP antibody in NHS. This band was also present and undiminished in sera depleted of C9 and of C8 and C9.
To investigate whether anti-MIP-reactive material was also present in other biological fluids, saliva, urine and cerebrospinal fluid were electrophoresed and immunoblotted as described above. Fig. 3 shows the presence in all of these fluids of a band of molecular mass identical with that seen in serum. The band from cerebrospinal fluid was very broad, perhaps reflecting overloading of the track, or heterogeneity arising from using pooled, concentrated cerebrospinal fluid. Isolation of MIP from plasma As noted above, the polyclonal anti-MIP antibody showed weak cross-reactivity with C8 and C9. To prevent saturation of the anti-MIP affinity column plasma was therefore specifically depleted of these components on monoclonal antibody affinity columns. The depleted plasma was then subjected to immunoaffinity chromatography on a solid-phase polyclonal anti-(erythrocyte membrane MIP) column.
On SDS/PAGE the purified protein had a molecular mass of 55 kDa under non-reducing conditions, and 65 kDa on reduction, identical with that of the membrane-derived protein isolated as described above (Fig. 4) reduction implies further unfolding as a result of disulphide bond cleavage. All preparations also contained high-molecular-mass aggregates just entering the separating gel (molecular mass > 200 kDa) which on reduction co-migrated with the monomer or, in some preparations, produced two lower-molecular-mass bands of approx. 50 and 20 kDa. Aggregates were also present in our preparations of membrane MIP and the relative proportions of aggregate to monomer increased on storage of both proteins, even at -20 'C. A minor band of molecular mass 85-90 kDa was often present in preparations of MIP from plasma and membrane and was detected by both polyclonal and monoclonal anti-MIP antibodies. The yield of MIP from plasma in several preparations was between 1.5 and 2.0 mg/l. The antibody column has now been used over 20 times with no appreciable loss of efficiency.
Production of monoclonal antibodies
Of the 576 wells screened following single-cell cloning of hybrid cells, five were strongly positive in an e.l.i.s.a. assay for anti-MIP reactivity. Of these, three were successfully grown up in bulk and injected intraperitoneally into mice to produce ascites fluid. Using class-and subclass-specific antisera two of these antibodies were IgG2, (MIP-B5 and MIP-D8) and the other was IgG2, (MIP-G3).
Effect of MIP depletion on the lytic activity of normal plasma Plasma was depleted of C8 and C9 because of the cross-reactivity noted previously, and half was applied to the anti-MIP affinity column. Pure C8 and C9 were added to restore levels to 50 ,ug/ml in both MIP-depleted and non-depleted sera and their lytic capacity compared in haemolytic assays utilizing antibody-sensitized sheep Plasma was immunochemically depleted of C8 and C9 and half was applied to the anti-MIP affinity column. Pure C8 and C9 were added back to restore levels to 50 ,tg/ml in both MIP-depleted and non-depleted plasmas and their lytic capacity compared in haemolytic assays utilizing sensitized sheep erythrocytes as target cells. Lysis is expressed as 'Z units' calculated as described in Whaley (1985) . Each point represents the mean value of triplicate determinations. 0, Plasma depleted of MIP; *, plasma containing MIP.
erythrocytes as target cells. Fig. 5 illustrates that plasma depleted of MIP was consistently more lytic towards the target erythrocytes than plasma containing MIP. Addition of pure MIP to a final concentration of about 50 jug/ml diminished lytic activity in the depleted serum. E.l.i.s.a. assay for MIP in biological fluids A two-site e.l.i.s.a. assay utilizing polyclonal anti-MIP as first antibody and monoclonal anti-MIP G3 as second antibody was used to quantify MIP in plasma, urine and cerebrospinal fluid. The detection limit of the assay was 0.01 mg/l and the working range (< 10 o CV) was 0.01-0.25 mg/l. All samples were diluted to bring the measured concentration within this working range. Dilution and recovery studies showed satisfactory linearity. The mean concentration of MIP in 10 normal plasma samples was 2.5 mg/l (range 1.2-2.9 mg/l, S.E.M. 0.18 mg/l), in urine the mean MIP concentration was 0.08 mg/l (n = 10, range 0.04-0.11 mg/l, S.E.M. 0.007 mg/l), and in cerebrospinal fluid the mean MIP concentration was 0.35 mg/l (n = 10, range 0.1-0.49 mg/l, S.E.M. 0.041 mg/l).
DISCUSSION
Since the description in the 1950s of a serum protein with Cl esterase inhibitory activity (Levy & Lepow, 1959) a large number of fluid-phase and membraneassociated proteins with complement controlling activity have been described (reviewed in Buscher & Opferkuch, 1988 Zalman et al., 1986; Watts et al., 1987) . Functional and physicochemical similarities suggest that all three of these proteins are identical, a supposition supported by the demonstration of cross-reactivity of antiserum raised against C8bp (donated by G. M. Hansch) with MIP (M. J. Watts & B. P. Morgan, unpublished work) . We have chosen to call our protein MAC-inhibitory protein (MIP) because neither of the other names is entirely appropriate. The protein does not solely bind C8, nor, at least in our hands, is its lytic inhibitory activity completely restricted to homologous systems. These molecules on incubation with cells re-incorporate into the membrane rendering the cell less susceptible to lysis by complement, particularly of the same species, and have also been reported to inhibit lysis by killer lymphocytes (Zalman et al., 1987b (Zalman et al., , 1988 ). Hansch and co-workers have reported that C8bp interacts with the y-subunit of C8 and diminishes lysis by inhibiting polymerization of C9 in the MAC (Hansch et al., , 1987 Schonermark et al., 1988) .
Several similarities exist between MIP and decayaccelerating factor (DAF). Both have been identified on circulating cells and have been implicated in the protection of homologous cells from complement lysis. More recently it has been shown that both of these proteins are deficient in blood cells from patients with paroxysmal nocturnal haemoglobinuria (Hansch et al., 1987; Zalman et al., 1987a; Halperin & NicholsonWeller, 1989) , and that C8bp (HRF/MIP), like DAF, is linked to the membrane by a phosphatidylinositol linkage . DAF has been demonstrated in body fluids, including plasma, tears, saliva and urine (Medof et al., 1987) . It therefore seemed possible that MIP would also be detectable in biological fluids.
Here we report the identification in plasma, urine, saliva and cerebrospinal fluid of a protein immunochemically identical with and functionally similar to that of the membrane-derived MAC-inhibiting proteins. Plasma, urine, saliva and cerebrospinal fluid MIP had similar molecular masses to and reacted with antibodies raised against the membrane form. The protein has been purified from plasma and monoclonal antibodies raised against plasma MIP all recognized membrane MIP. The concentration of the protein in normal plasma measured by e.l.i.s.a. was about 2.5 mg/I, and the yield from several purifications was between 1.5 and 2.0 mg/l, a recovery of 60-80 %. The protein was immunochemically distinct from S protein and DAF as demonstrated by immunoblotting with monoclonal and polyclonal antibodies against these proteins (results not shown).
Unlike membrane-derived MAC-inhibitory proteins, purified plasma MIP did not spontaneously incorporate into cell membranes and inhibit lysis by the MAC, a further analogy with the properties of DAF, the urinederived form of which cannot reinsert into membranes (Medof et al., 1987) . However, when sheep erythrocytes were lysed with human serum, or when human erythrocytes were attacked with homologous serum, MIP was deposited on the cell surface ( Figs. 1 and 2) . Thus, soluble MIP, though not able to spontaneously incorporate into membranes, is deposited on membranes during complement_attack on heterologous or homologous target cells. Deposited MIP was detected on the cell surface by antibody much more efficiently than the membrane protein, suggesting that it was present in a different conformation. The electron-microscopic studies also provided evidence of the stage of MAC assembly at which MIP binds. Deposition of MIP was not affected by the removal of C9 but was greatly inhibited in the absence of C8, suggesting that plasma MIP binding requires the C5b-8 complex. These data support the findings of Hansch and co-workers (Schonermark et al., 1988) , who have shown that C8bp (MIP/HRF) isolated from membranes binds to C8 in the MAC. Uptake of plasma MIP mediated by the MAC may render the cell less susceptible to subsequent attack, providing a mechanistic explanation for the intriguing findings of Houle et al. (1988) , who showed that attack by homologous complement rendered cells resistant to lysis even by heterologous complement during a second attack.
In an attempt to demonstrate a functional role for fluid-phase MIP we depleted human serum of MIP. This resulted in enhancement of the lytic capacity of the serum on heterologous cells and restoration of MIP decreased lysis, providing evidence that fluid-phase MIP plays a role in the modulation of lysis by the MAC (Fig.  5) . The concentration of MIP necessary to decrease the lytic activity of MIP-depleted serum back to the predepletion levels was much higher than the measured serum concentration, implying that functional activity was lost dunrng the purification.
The source of soluble MIP is as yet uncertain, though the close similarities with the membrane protein suggest a common origin. Cells bearing MIP may constitutively secrete the protein as well as incorporating it into their membranes, or alternatively, soluble MIP may be derived from the membrane form, perhaps during the process of cell ageing. MIP, like DAF, has been shown to be linked to the membrane via a glycolipid membrane anchor , which may be slowly cleaved by endogenous phospholipases, releasing the protein. Although by gel electrophoresis the two proteins appeared to be of identical molecular masses, the possibility of cleavage close to or at the membrane-binding region remains.
The mechanism of action of soluble MIP remains uncertain. Our evidence suggests that it becomes associated with the membrane during MAC assembly, and may then function in a similar way to the membraneassociated form, interfering with C9 polymerization and thereby inhibiting MAC activity. Its biological importance also remains to be established. MIP is present in plasma and, intriguingly, in cerebrospinal fluid in relatively high concentrations. It may therefore play a part in the modulation of the effects of complement activation on cells exposed to these fluids.
